Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 58.17

+3.9%

Dec 4 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: BulbaMan who wrote (9145)	9/17/2003 9:30:25 AM
From: Biomaven	of 52153

Anyone have a clue as to why Genta/Aventis highlighted the confusing, combined data for all 771 patients? Because that was the pre-determined endpoint of the trial. Likely it should not have been, particularly after they added more patients later than originally planned. as the benefits of Genasense were never expected to show up until after 6-8 months elapsed. They didn't know this ahead of time. Remember that's a median expected survival - half the patients die before that mark. If the drug worked dramatically then virtually all the patients that died would have been on the placebo and they could easily have achieved significance in this time frame. Has anyone asked the company for the Kaplan-Meier curves they presented at the analyst meeting? Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next